Posted in | News | 3D Printing

Adaptive3D Secures Arkema-led Series B Investment

Adaptive3D furthers its mission of providing materials to enable 21st-century manufacturing by securing Series B financing from a syndicate led by the Arkema Group and bolstered by West Pharmaceutical Services, Clear Fir Partners, and current investors including Applied Ventures and the founding family of Texas Instruments.

Adaptive3D sells photopolymer resins to enable the additive manufacturing of tough, strain-tolerant, tear-resistant rubbers, such as its flagship product, Elastic ToughRubber 90™: a tough, printable elastomer for all seasons. Adaptive3D printable photo-resins are optimized for high-throughput manufacturing of functional complex 3-dimensional plastic and rubber parts in consumer, healthcare, industrial, transportation and oil and gas markets. Arkema and West Pharmaceutical Services exemplify the potential end points of a complete additive manufacturing ecosystem, from new material development, scaled specialty resin manufacturing to functional end-use parts.

“Challenging the aging model of injection-molded rubbers and polyurethanes, Adaptive3D is now scaling production and distribution to deliver shelf-stable, print-stable, one-part photoresins that yield superior, manufactured end parts,” said President and CEO Walter Voit, PhD. “Our resins enable customers to topologically optimize and micro-architect their polymeric products to provide a sustainable competitive advantage now.”

“Arkema is a global leader in supplying specialty materials to enable sustainable, innovative solutions to manufacturing technologies,” said Sumeet Jain, the Senior Director of 3D Printing worldwide at Arkema. “Adaptive3D photoresins, based on Arkema materials and now validated in the market, further our customer-focused mission to reach into new application spaces with 21st-century materials. Adaptive3D delivers compelling materials properties with ease of printing and post-processing—a great step forward for the whole additive manufacturing field.”

“At West, we see the potential of additive manufacturing to create differentiated, novel components and solutions for the healthcare sector,” said Scott Young, PhD, VP Research Innovation & Technology at West Pharmaceutical Services. “We understand well the challenges of commercializing new materials for the pharmaceutical packaging space, from innovation to validation to manufacturing at scale.  We are impressed with the science and expertise at Adaptive3D. We are excited about their current and future engineered photo resins and look forward to working with Adaptive3D to push forward the technology boundaries of pharmaceutical packaging services.”


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Adaptive3D Technologies. (2020, October 28). Adaptive3D Secures Arkema-led Series B Investment. AZoM. Retrieved on May 22, 2024 from

  • MLA

    Adaptive3D Technologies. "Adaptive3D Secures Arkema-led Series B Investment". AZoM. 22 May 2024. <>.

  • Chicago

    Adaptive3D Technologies. "Adaptive3D Secures Arkema-led Series B Investment". AZoM. (accessed May 22, 2024).

  • Harvard

    Adaptive3D Technologies. 2020. Adaptive3D Secures Arkema-led Series B Investment. AZoM, viewed 22 May 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.